Fresh analysis suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional lifestyle programs.
Findings released in a leading health publication points out that while obese individuals can lose about a fifth of their body weight while on the medication, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People using these treatments must be informed of the danger of fast rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to starting mass in about a year and a half.
Weighing Approaches
The analysis, which looked at 37 of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually see a less rapid creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Nutrition scientists believe the mode of action of the jabs is key to understanding the accelerated weight return.
The injections imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, due to the high risk of relapse, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who note that the results "emphasize the chronic character of obesity," comparing it to managing conditions like diabetes.
User Accounts
Users who have come off the jabs report a sudden return of cravings.
"It felt as if a trigger flipping and you become ravenous," described one woman.
This difficulty is compounded if patients have not developed sustainable lifestyle or habit modifications during treatment.
Significant Adoption
Figures show that a significant number of adults in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and long-term success hinges on combined behavioural changes.
